. 2011 Feb 23;2(4):313–315. doi: 10.1021/ml1003074

Table 1. Cytotoxicity Evaluation of (−)-(R)- and (+)-(S)-Boehmeriasin A in Comparison to Paclitaxel^a.

	IC₅₀ (nM)
compd	COLO-205	MCF-7	NCI-ADR-RES
paclitaxel^b	3.31	1.62	>6400
(−)-(R)-1·HCl^c	4.18	43.4	36.7
(+)-(S)-1·HCl^b	103	92.7	434

COLO-205 = human colorectal adenocarcinoma (GI₅₀ = 0.80 nM reported for (−)-1; see ref (1)); MCF-7 = human breast carcinoma (GI₅₀ = 13 nM reported for (−)-1; see ref (1)); NCI-ADR-RES = drug-resistant human ovarian adenocarcinoma.

Average of six assays each.

Average of three assays each.

Table 1. Cytotoxicity Evaluation of (−)-(R)- and (+)-(S)-Boehmeriasin A in Comparison to Paclitaxela.

Table 1. Cytotoxicity Evaluation of (−)-(R)- and (+)-(S)-Boehmeriasin A in Comparison to Paclitaxel^a.